In an effort to identify c/s-acting elements required for targeting of the somatic hypermutation process in mice, we examined whether a T cell receptor (TCR) transgene under the control of the immunoglobulin (Ig) heavy (H) chain intron enhancer would be mutated in antigenstimulated B cells. Hybridomas were established from splenic B cells of mice carrying two copies of the TCR transgene after hyperimmunization with phosphorylcholine keyhole limpet hemocyanin. Northern analysis revealed that all of the transgene-containing hybridomas expressed the TCR mRNA. Multiple somatic point mutations were found in seven of eight endogenous Ig VH genes examined. In contrast, 29 of 32 TCR genes examined contained no mutations. One potential mutation was seen in each of the three other TCR genes. Our data indicate that although the TCR transgene is expressed in B cells, it is not efficiently targeted by the mutator mechanism. Furthermore, the presence of an Ig H chain enhancer is itself not sufficient for targeting of the somatic hypermutation mechanism.
S
omatic hypermutation of Ig genes after antigenic stimulation of B cells is an important mechanism for diversification of the immune repertoire (reviewed in 1, 2). The rate of antigen-induced somatic hypermutation of Ig V region genes has been estimated at up to 10-Ubp/cell generation (3) . Although both productively and nonproductively rearranged V genes are targeted, constant regions are spared (4) (5) (6) (7) . This process appears to be unique to B cells, in that somatic hypermutation does not appear to play a significant role in diversification of TCR genes in T cells.
The molecular mechanism responsible for selectively introducing the characteristic single-base substitutions into Ig V regions and their flanking sequences is unknown. Although gene conversion appears to play a critical role in generation of the immune repertoire in chickens (8, 9) and rabbits (It)), a significant role in somatic mutation of Ig genes in mice or humans has not been found (11, 12) . The nature and localization of mutations in humans and mice are suggestive of a mechanism involving targeted point mutations (5, (13) (14) (15) (16) (17) .
We and others have shown that rearranged Ig transgenes can be targeted by the somatic hypermutation mechanism (17) (18) (19) (20) (21) . The nature and localization of mutations are similar to those seen in endogenous Ig genes (20, 21) . The ability of the mutator mechanism to target these Ig transgenes, independent of their chromosomal location, suggests that they contain any required c/s-acting elements. In an effort to define potential targeting requirements of the somatic hypermutation machinery, we examined whether a rearranged TCR gene, when expressed in B cells, would be targeted by the mutator mechanism.
Materials and Methods
Mice. Generation of the 2B4/8-L mouse line carrying two copies of the 2B4/fE. transgene (see Fig. 1 ) has been described previously (22) .
Generation and Screening of Hybridomas. A 2B4~-L transgenic mouse ([C57BL/6 • C3H/HeJ]F2 backcrossed to C57BL/6) was immunized intraperitoneally with phosphorylcholine (PC)I-KLH as follows: 0.1 mg in CFA on day -120, 0.1 nag in IFA on day -78, and 0.1 mg in PBS on days -53, -3, and -1, relative to fusion of spleen cells with the myeloma X63-AgS.653 as described (23) . Hybridomas were screened by ELISA for secretion of IgM or IgG, PC-BSA binding (18) , and subsequently cloned by limiting dilution. In cases where IgG subclass is indicated, this was Abbreviations used in this paper: E,, Ig heavy chain enhancer; L, leader; PC, phosphorylcholine.
determined by DNA sequencing. Determination of whether the hybridomas contained the transgene was carried out using PCK analysis (24) Northern Blot Analysis. Northern blot analysis was performed with 20 #g of total RNA. To assay 2B4flE. transgene expression, blots were probed with a 574-bp fragment encompassing the VDJ region amplified with the primers 2B4-1 and 2B4-2 by PCR (see above), or with a 2.6-kb fragment containing the 2B4 VDJ region isolated from a genomic done. To monitor expression of the V1 gene of the V.S107 family, blots were probed with a 189-bp V.-167-specific fragment (26) .
Nucleotide Sequencing. For sequence analysis of endogenous V. genes, total RNA was prepared by the guanidine isothiocyanate method (27) . First-strand DNA synthesis was carried out using (28) , along with the "/3 and X3" primers or M-CH1. A mix containing PCR buffer, 50 pmol of each primer, and 4 U Taq polymerase was added to the 10-#1 cDNA reaction to bring the total volume to 100 #1. A 25-cycle amplification was carried out on a GeneAmp 9600 (Perkin Elmer Cetus Corp.) with denaturation at 94~ for 30 s, annealing at 50~ for 30 s, and extension at 72~ for 60 s. Amplification products were isolated on 1% low-melt agarose (FMC Corp., Rockland, ME) gels, and blunt-end cloned into EcoRV-digested pBluescript KS + (Stratagene Inc., La Jolla, CA). CsCl-banded plasmid DNA or miniprep DNA prepared with Qiagen tip-20 columns (Qiagen, Inc., Chatsworth, CA) was alkali denatured and annealed to KS or SK primers (Stratagene Inc.). Sequencing was performed using the Sequenase kit (US Biochemicals, Cleveland, OH).
To sequence the 2B43E. transgenes, hybridoma DNA (40 #g) was digested with BamHI, and electrophoresed on 1% low-melt agarose gels to separate the two copies of the transgene L-VDJ region. Agarose blocks corresponding to the 2.8-3.5-and 6.0-16.0-kb regions were excised and melted at 65~ A 574-bp fragment encompassing the transgene L-VDJ region was amplified by PCR using the primers 2B4-1 and 2B4-2, as previously described (17) . 25 cycles of amplification were performed on a GeneAmp 9600 with denaturation at 94~ for 15 s, annealing at 55~ for 30 s, and extension at 72~ for 60 s. The PCK products were cloned and sequenced using the primer 2B4- KS and SK primers as previously outlined. In an effort to distinguish between somatic mutations and Taq polymerase errors, if potential mutations were identified, additional products of the original PCR were examined, or products from a second, independent, PCK reaction were sequenced. Alterations were considered to be actual mutations if they were still present in products of the second PCR reaction.
Results and Discussion
To define potential targeting requirements of the somatic hypermutation mechanism, we utilized the transgenic mouse line 2B4fl-L. The 2B4B-L line carries a low copy number of a rearranged genomic TCR-fl chain construct that lacks the native TCR-3 enhancer region (29-31), but contains an Ig H chain enhancer (E.) element between J and Cfl2 (2B43E., Fig. 1, reference 22 ). 2B43-L mice were hyperimmunized with PC-KLH, and spleen B cells were fused to that the 10F4 subclones had lost the transgene, and these were eliminated from further analysis. 8 of 16 hybridomas carrying the transgene expressed the V1 gene of V.$107 based on Northern analysis (data not shown) or RNA sequencing (Fig. 3) .
In previous experiments, the addition of an E. element to a TCR-ot chain construct resulted in the expression of this ot chain in transfected plasmacytoma (J558L) cells (33) . Furthermore, in experiments with transgenic mice carrying this TCR-ot chain gene under the control of the E., it was expressed in splenic B cells (33) . Consistent with these findings, Northern analysis revealed that the 1.3-kb B chain transcript is present in all B cell hybridomas that retained the 2B4/~E. transgene, as well as in spleen and thymocyte RNAs of 2B4/~-L mice (Fig. 2) . Thus, the E. control element provides for expression of the TCtL-B chain construct in B cells, as well as in T cells.
To establish whether the mutator mechanism was active in the B cells before fusion, we examined endogenous V.
genes expressed by the hybridomas. Primers specific for the CH1 domain of IgM or IgG were used to specifically prime first-strand DNA synthesis. These products were amplified by pcp,, cloned, and sequenced (Fig. 3) . Only hybridomas using the V1 gene of the V8S107 family are shown. Since there are only four members in the $107 family (32), mutations of V1 can be scored with greater confidence than V genes in the larger V. families. In all cases, cloned V1 genes contain the allelic substitutions found in the C57BL/6 germline gene (34, 35) . Seven of the eight expressed V1 genes were mutated, with the number of mutations ranging from 3-11. A total of 52 single base substitutions were observed over a total of 2.4 kb analyzed. In a few cases, mutations were shared between V1 genes in different hybridomas. It is conceivable that some (but not all) of these may represent C3H/HeJ allelic differences, as the germline sequence has not been determined. Clearly, the mutator mechanism had been active in the majority of the B cells before fusion.
To determine if the TCR transgene was mutated, a 574- bp fragment encompassing the 2B4/3E. I_,VDJ region (Fig.  4) was amplified from hybridoma DNA by PCR, cloned, and sequenced. This region was chosen because in K transgenes the analogous region was heavily targeted by the somatic hypermutation process (17, 20, 21) . Preliminary analysis of 2B4B-L transgenic DNA revealed that there are two copies of this target region. In all cases, including transgenic kidney DNA, clones were generated that contained a T at position 227 within the L-V intron, in addition to clones with a C (published sequence, 25) at this position. BamHI digestion and Southern analysis revealed two single-copy bands hybridizing to the 2B4/3 VDJ and E. probes, one at the expected 7.5-kb range and one at 3 kb (data not shown).
Whether the smaller fragment has arisen because of a mutation leading to introduction of a new BamHI site (which might have occurred during transgene integration), or whether it represents a partial copy, has not been determined. The orientation of the two copies relative to each other is unknown. Amplification of the separated fragments demonstrated that the larger fragment (copy 1), contains a T at 227, while the smaller fragment (copy 2) has a C at this position. This substitution proved useful in distinguishing the cloned transgene products. 29 of 32 total TCR L-VDJ regions analyzed contained no mutations (Fig. 4) . Copy I cloned from hybridomas 1H2 and 4G6 contained a single mutation (A~G) at position 43, 5' of the L sequence. This identical substitution was seen in products of four other hybridomas, but was determined to be a PCR or cloning artifact, as it was not present in products of another PCR from these four hybridomas. Thus, the significance of this substitution in copy 1 from these two hybridomas is unknown, but we consider it likely that this position may represent a hot spot for PCR errors. Copy 1 cloned from 8G1 contained a single mutation (G---A) at position 508. This substitution was seen in products of three independent PCR amplifications of 8G1 DNA, and thus appears to be a somatic mutation, as it was not present in kidney DNA or the other hybridomas.
Thus, in 17.5 kb of TCR sequence examined (two copies from 16 different hybridomas), only three potential somatic mutations have been identified. Of these, two are an identical substitution found at the same position. If this alteration is somatic in nature, it is conceivable that it occurred early in B cell development, before the onset of somatic hypermutation, and is shared by progeny of this clone.
In any case, the frequency of mutations in the TCR genes (0.017% if all three substitutions are included) is markedly reduced as compared with that seen in the expressed V. genes (2.1%). These data indicate that although the TCR /3 chain gene is expressed in B cells, it is not efficiently targeted by the somatic hypermutation mechanism. In contrast to B cells, evidence of somatic hypermutation has not been documented in T cells. These data suggest that TCK genes do not contain cis-acting elements required for recognition by the mutator mechanism. However, it is not known whether the mutator mechanism is ever activated in T cells. Most likely it is not, and the lack of observed somatic mutations in TCR V genes could be due to the combined absence of cis-acting elements and the mutator.
One trivial explanation for the observed lack of targeting of this TCK gene by the mutator mechanism could be an inhibitory effect of the transgene insertion site. However, the ability to demonstrate expression of the transgene suggests that it should be accessible to the mutation process. In multiple cases where ~ or H transgenes have been examined, they have functioned as substrates for the mutation process (17) (18) (19) (20) (21) . These data are consistent with the notion that targeting of Ig transgenes can occur independent of chromosomal location, as long as they are accessible to the mutator mechanism.
An Ig H chain transgene containing only the intron E. appears to function as a substrate for the somatic hypermutation mechanism (19) . However, based on our data, although the Ig E. element may be required for somatic mutation, it is not sufficient to provide efficient targeting of the mutator mechanism. This is interesting, as truncated ~ transgene constructs lacking the 3' K enhancer (36) do not appear to be targeted for somatic hypermutation (37, 38) , even if expressed at high levels (38) . This suggested a cis-acting role for the 3' enhancer element in the process. Whether it is required for actual recognition of the Ig substrate by the mutator mechanism, or is important for maintaining transcription of the gene while the mutator mechanism is active, is unknown.
Recent analysis of the localization pattern of mutations in endogenous K and H genes and in multi-copy K transgenes (17, 20, (39) (40) (41) have led to the suggestion that critical cisacting elements may be located 5' to the V genes. Conceivably, the TCR gene differs in this upstream region in a sequence which is essential for targeting the mutation process. The TCR construct used in this study included 4.5 kb of genomic sequence upstream of the leader. It would be interesting to see if the introduction of 5' K sequences would make this TCR gene a substrate for somatic hypermutation.
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